1. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F (2007) Phase II study of vandetanib or placebo in small cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy. National cancer institute of canada council trials group study BR.20. J Clin Oncol 25:4278–4284
2. Arteaga C (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32S–40S
3. Blay JY, L. C. (2005) Targeted cancer therapies. Bull Cancer 92:E13–E18
4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365
5. Bukowski RM, K. F. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol 24(suppl):4523a. Abstract 4523